CVE:BTI

Bioasis Technologies Stock Forecast, Price & News

C$0.28
-0.01 (-3.45 %)
(As of 07/26/2021 03:29 PM ET)
Add
Compare
Today's Range
C$0.27
C$0.28
50-Day Range
C$0.26
C$0.39
52-Week Range
C$0.23
C$0.70
Volume21,189 shs
Average Volume68,369 shs
Market CapitalizationC$20.20 million
P/E Ratio28.00
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BTI News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioasis Technologies and its competitors with MarketBeat's FREE daily newsletter.


About Bioasis Technologies

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders, including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). Bioasis Technologies Inc. has a research collaboration with Aposense Limited to focus on the delivery of siRNA into the brain. The company was incorporated in 2006 and is headquartered in New Haven, Connecticut.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.54 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Bioasis Technologies (CVE:BTI) Frequently Asked Questions

What stocks does MarketBeat like better than Bioasis Technologies?

Wall Street analysts have given Bioasis Technologies a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bioasis Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Bioasis Technologies' stock been impacted by Coronavirus (COVID-19)?

Bioasis Technologies' stock was trading at C$0.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BTI shares have increased by 47.4% and is now trading at C$0.28.
View which stocks have been most impacted by COVID-19
.

Is Bioasis Technologies a good dividend stock?

Bioasis Technologies pays an annual dividend of C$2.02 per share and currently has a dividend yield of 0.00%. The dividend payout ratio of Bioasis Technologies is 20,200.00%. Payout ratios above 75% are not desirable because they may not be sustainable.
View Bioasis Technologies' dividend history.

Who are Bioasis Technologies' key executives?

Bioasis Technologies' management team includes the following people:
  • Dr. Deborah Ann Rathjen B.Sc. (Hons.), Q.C., Ph.D., M.A.I.C.D., FTSE, Exec. Chairman, CEO & Pres (Age 63, Pay $191.81k)
  • Ms. Christine Antalik, Chief Financial Officer (Age 50, Pay $223.54k)
  • Mr. Graeme Dick, Director of Investor Relations
  • Mr. Kim Elton, Director of Marketing
  • Mr. Doug Williams MBA, Exec. VP & Chief Bus. Officer
  • Dr. Mei Mei Tian, VP & Head of External Research
  • Dr. May Orfali, Consultant Chief Medical Officer

Who are some of Bioasis Technologies' key competitors?

What other stocks do shareholders of Bioasis Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bioasis Technologies investors own include Praxair (PX), OrganiGram (OGI), Morningstar (MORN), Five Below (FIVE), Extendicare (EXE), General Cannabis (CANN), Blackstone Mortgage Trust (BXMT) and Bank of America (BAC).

What is Bioasis Technologies' stock symbol?

Bioasis Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "BTI."

How do I buy shares of Bioasis Technologies?

Shares of BTI and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Bioasis Technologies' stock price today?

One share of BTI stock can currently be purchased for approximately C$0.28.

How much money does Bioasis Technologies make?

Bioasis Technologies has a market capitalization of C$20.20 million and generates C$4.08 million in revenue each year.

What is Bioasis Technologies' official website?

The official website for Bioasis Technologies is www.bioasis.ca.

Where are Bioasis Technologies' headquarters?

Bioasis Technologies is headquartered at 130-10691 Shellbridge Way, RICHMOND, BC V6X 2W8, Canada.

How can I contact Bioasis Technologies?

Bioasis Technologies' mailing address is 130-10691 Shellbridge Way, RICHMOND, BC V6X 2W8, Canada. The company can be reached via phone at +1-604-2957014.


This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.